Cargando…

Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers

Biglycan (BGN), a key member of the small leucine-rich proteoglycan family, is an important component of the extracellular matrix. Clinical studies have demonstrated that upregulation of BGN is associated with poor prognosis in patients with various types of solid cancer. The present study analyzed...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shou-Feng, Yin, Xue-Jing, Zhao, Wen-Ju, Liu, Le-Cui, Wang, Zhi-Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039163/
https://www.ncbi.nlm.nih.gov/pubmed/32194659
http://dx.doi.org/10.3892/ol.2020.11266
_version_ 1783500772275650560
author Zhao, Shou-Feng
Yin, Xue-Jing
Zhao, Wen-Ju
Liu, Le-Cui
Wang, Zhi-Peng
author_facet Zhao, Shou-Feng
Yin, Xue-Jing
Zhao, Wen-Ju
Liu, Le-Cui
Wang, Zhi-Peng
author_sort Zhao, Shou-Feng
collection PubMed
description Biglycan (BGN), a key member of the small leucine-rich proteoglycan family, is an important component of the extracellular matrix. Clinical studies have demonstrated that upregulation of BGN is associated with poor prognosis in patients with various types of solid cancer. The present study analyzed the mRNA expression levels of BGN in various types of solid cancer when compared with that in normal tissues via the Oncomine database. The UALCAN, OncoLnc and Kaplan-Meier Plotter databases were additionally used to evaluate the prognostic values of BGN in patients with solid cancer and co-expression gene analysis was conducted using the protein-protein interaction networks of BGN. The present study observed that the mRNA expression levels of BGN were increased in bladder, brain and central nervous system, breast, colorectal, esophageal, gastric, head and neck, lung, ovarian and 28 subtypes of cancer compared with normal tissues. The increased expression of BGN was identified to be associated with a poor outcome in ovarian and gastric cancer. Based on the co-expression network, BGN was identified as the key gene in a 43-gene network. The present findings of increased expression of BGN in solid tumors and its positive association with poor outcome on patient survival indicate that BGN may serve as a prognostic marker and as a target for novel therapeutics for multiple types of cancer.
format Online
Article
Text
id pubmed-7039163
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-70391632020-03-19 Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers Zhao, Shou-Feng Yin, Xue-Jing Zhao, Wen-Ju Liu, Le-Cui Wang, Zhi-Peng Oncol Lett Articles Biglycan (BGN), a key member of the small leucine-rich proteoglycan family, is an important component of the extracellular matrix. Clinical studies have demonstrated that upregulation of BGN is associated with poor prognosis in patients with various types of solid cancer. The present study analyzed the mRNA expression levels of BGN in various types of solid cancer when compared with that in normal tissues via the Oncomine database. The UALCAN, OncoLnc and Kaplan-Meier Plotter databases were additionally used to evaluate the prognostic values of BGN in patients with solid cancer and co-expression gene analysis was conducted using the protein-protein interaction networks of BGN. The present study observed that the mRNA expression levels of BGN were increased in bladder, brain and central nervous system, breast, colorectal, esophageal, gastric, head and neck, lung, ovarian and 28 subtypes of cancer compared with normal tissues. The increased expression of BGN was identified to be associated with a poor outcome in ovarian and gastric cancer. Based on the co-expression network, BGN was identified as the key gene in a 43-gene network. The present findings of increased expression of BGN in solid tumors and its positive association with poor outcome on patient survival indicate that BGN may serve as a prognostic marker and as a target for novel therapeutics for multiple types of cancer. D.A. Spandidos 2020-03 2020-01-08 /pmc/articles/PMC7039163/ /pubmed/32194659 http://dx.doi.org/10.3892/ol.2020.11266 Text en Copyright: © Zhao et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Zhao, Shou-Feng
Yin, Xue-Jing
Zhao, Wen-Ju
Liu, Le-Cui
Wang, Zhi-Peng
Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers
title Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers
title_full Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers
title_fullStr Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers
title_full_unstemmed Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers
title_short Biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers
title_sort biglycan as a potential diagnostic and prognostic biomarker in multiple human cancers
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039163/
https://www.ncbi.nlm.nih.gov/pubmed/32194659
http://dx.doi.org/10.3892/ol.2020.11266
work_keys_str_mv AT zhaoshoufeng biglycanasapotentialdiagnosticandprognosticbiomarkerinmultiplehumancancers
AT yinxuejing biglycanasapotentialdiagnosticandprognosticbiomarkerinmultiplehumancancers
AT zhaowenju biglycanasapotentialdiagnosticandprognosticbiomarkerinmultiplehumancancers
AT liulecui biglycanasapotentialdiagnosticandprognosticbiomarkerinmultiplehumancancers
AT wangzhipeng biglycanasapotentialdiagnosticandprognosticbiomarkerinmultiplehumancancers